Timolol: Clinical Trials

58 trials of Timolol, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

43 completed, 5 terminated, 5 unknown, 3 withdrawn. 58 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 458Completed 43, Terminated 5, Unknown 5, Withdrawn 3, Active not recruiting 1, Recruiting 1

Follow Timolol: new trials by email Literature Review of Timolol trials Research Report on Timolol

Trials (filtered) newest first · largest first

All 58 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Adaptive Optics OCT Evaluation of Rhopressa's Effects on the Retinal Ganglion Cells in Glaucoma Patients
Netarsudil 0.02% Ophthalmic Solution [RHOPRESSA], Timolol Maleate 0.25% Ophthalmic Solution - Open Angle Glaucoma (OAG), Glaucoma
Phase 4RecruitingBrett King132026-10-012026-10-28
How Much Does Reduced Dosing of Latanoprost and Dorzolamide-timolol Affect Pressure?
dorzolamide/timolol - Glaucoma, Open-Angle, Glaucoma; Drugs
Phase 4TerminatedCT Glaucoma Associates362024-04-222024-08-23
Assessing the Impact of Dosage Frequency of Propranolol on Sleep Patterns in Patients With Infantile Hemangiomas
Propranolol three times a day, Propranolol twice a day, Timolol - Infantile Hemangioma
Phase 4TerminatedThe University of Texas Health Science Center, Houston522022-06-232026-03-13
Comparison of Efficacy and Ocular Surface Assessment Between BRIDIN-plus and Combigan in Glaucoma or Ocular Hypertensive
BRIDIN-plus Eye drops, Combigan Eye drops - Glaucoma, Ocular Hypertensive
Phase 4CompletedCHA University602021-10-082025-03-26
Triplenex (triple Fixed Combination) Use Evaluation in Patients with Glaucoma
Triple combination formula, Bimatoprost .03% sterile ophthalmic solution - Glaucoma, Quality of Life (QOL)
Phase 4Active not recruitingFederal University of São Paulo402021-03-012025-01-07
Aqueous Humor Dynamic Components That Determine Intraocular Pressure Variance
Timolol 0.5% ophthalmic solution, Latanoprost 0.005% Ophthalmic Solution - Glaucoma, OHT - Ocular Hypertension
Phase 4CompletedOhio State University592020-11-232026-03-04
24-hour Efficacy and Tolerability of the Tafluprost-timolol Fixed Association Without Preservatives in Glaucomatous or Ocular Hypertensive Patients Already Treated With Latanoprost Preserved With BAK. A Prospective, Open Study of 3 Months Duration.
tafluprost/timolol - Glaucoma, Open-Angle, Ocular Hypertension
Phase 4UnknownFondazione G.B. Bietti, IRCCS432020-06-042022-03-29
Evaluation of the Efficacy of Captopril Versus Propranolol and Timolol as a Treatment of Infantile Capillary Hemangioma
oral propranolol, Oral Captopril, intralesional propranolol injection - Infantile Hemangioma
Phase 4UnknownAin Shams University1002019-10-012020-02-28
Efficacy and Safety of Latanoprost/Timolol for Primary Open Angle Glaucoma
Latanoprost/Timolol - Primary Open Angle Glaucoma
Phase 4UnknownUniversiti Kebangsaan Malaysia Medical Centre402019-01-022019-09-23
Peripapillary Blood Flow After Use of Anti-glaucoma Medications: An OCT Angiography Study
Timolol Maleate, Brimonidine Tartrate - Glaucoma; Drugs, Normal Tension Glaucoma
Phase 4CompletedWills Eye352017-07-102020-12-31
Safety and Efficacy of SIMBRINZA® BID as an Adjunctive to DUOTRAV®
Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension, Brinzolamide/brimonidine vehicle, Travoprost 0.004%/timolol 0.5% solution - Open-angle Glaucoma, Ocular Hypertension
Phase 4TerminatedAlcon Research1732016-06-242019-05-29
24-hour Efficacy and Ocular Surface With Talfuprost and Triple Combined Therapy
tafluprost, tafluprost and dorzolamide/timolol - Glaucoma, Ocular Surface Disease
Phase 4CompletedAristotle University Of Thessaloniki432015-03-012020-12-17
Comparison of Intraocular Pressure (IOP)-Lowering Efficacy and Safety of AZORGA® Ophthalmic Suspension and COSOPT® Ophthalmic Solution
Brinzolamide 1%/Timolol maleate 0.5% fixed combination ophthalmic suspension, Dorzolamide hydrochloride 1%/Timolol maleate 0.5% ophthalmic solution, Subject's habitual PGA monotherapy - Open-Angle Glaucoma, Ocular Hypertension
Phase 4CompletedAlcon, a Novartis Company2182014-12-012016-12-08
The Secondary Beneficial Effects of Prostaglandin Analog Treatment in Thyroid Eye Disease Patients.
Prostaglandin Analog, Timolol - Thyroid Eye Disease, Ocular Hypertension
Phase 4WithdrawnStanford University2014-06-012018-05-15
Efficacy and Safety Study of Bimatoprost 0.01% Alone Compared With Travoprost 0.004% and Timolol 0.5% in Subjects With Glaucoma or Ocular Hypertension
bimatoprost 0.01%, travoprost 0.004%, timolol 0.5% - Glaucoma, Ocular Hypertension
Phase 4CompletedAllergan1002014-05-012016-01-14
Choroidal Thickness and Its Correlations With Ocular Parameters in Primary Open-angle Glaucoma
Brimonidine Tartrate, Dorzolamide (as Dorzolamide Hydrochloride) 20 Mg/mL and Timolol (as Timolol Maleate) 5 Mg/mL Eye Drops, Brinzolamide/Timolol 10 MG/1 ML-5 MG/1 ML Ophthalmic Suspension - Glaucoma, Open-Angle
Phase 4CompletedAfyon Kocatepe University Hospital962014-01-012019-05-29
Efficacy of Travoprost/Timolol for Uncontrolled Intraocular Pressure
Beta-blocker monotherapy, Travoprost 0.004% / timolol 0.5% fixed combination ophthalmic solution - Open Angle Glaucoma, Ocular Hypertension
Phase 4CompletedAlcon Research1572013-12-012016-08-08
Evaluation of Intraocular Pressure Using Simbrinza™ in Patients With Open-Angle Glaucoma or Ocular Hypertension
Brinzolamide 1%/Brimonidine 0.2% ophthalmic suspension, Timolol Maleate 0.5% - Open-Angle Glaucoma, Ocular Hypertension
Phase 4CompletedAlcon Research892013-10-012015-04-13
An Efficacy and Safety Study of Bimatoprost 0.01% Alone Compared With Travoprost 0.004% and Timolol 0.5% in Subjects With Glaucoma or Ocular Hypertension
bimatoprost 0.01%, travatan 0.004%, timolol 0.5% - Glaucoma, Ocular Hypertension
Phase 4CompletedAllergan932013-06-012015-11-30
Assessing the Efficacy of DuoTrav as a Replacement Therapy in Glaucoma Patients in Russia
Travoprost 0.004%/Timolol 0.5% Fixed Combination (DuoTrav) - Glaucoma, Ocular Hypertension
Phase 4WithdrawnAlcon Research2013-02-012013-02-07

Showing 20 of 58. Sign in to see all of them.

Conditions studied

Glaucoma (33)  ·  Glaucoma, Open-Angle (31)  ·  Ocular Hypertension (30)  ·  Eye Diseases (3)  ·  Hemangioma, Capillary (2)  ·  Low Tension Glaucoma (2)  ·  Exfoliation Syndrome (1)  ·  Glaucoma, Angle-Closure (1)  ·  Graves Disease (1)  ·  Graves Ophthalmopathy (1)  ·  Patient Compliance (1)

Sponsors

Alcon Research (16)  ·  Allergan (10)  ·  Aristotle University Of Thessaloniki (4)  ·  Pharmaceutical Research Network (3)  ·  Bp Consulting, Inc (2)  ·  Afyon Kocatepe University Hospital (1)  ·  Ain Shams University (1)  ·  Alcon, a Novartis Company (1)  ·  Brett King (1)  ·  CHA University (1)  ·  CT Glaucoma Associates (1)  ·  Credit Valley EyeCare (1)  ·  Federal University of São Paulo (1)  ·  Fondazione G.B. Bietti, IRCCS (1)  ·  Glaukos Corporation (1)

Countries

United States (23)  ·  Canada (8)  ·  Greece (4)  ·  Germany (3)  ·  Italy (3)  ·  Spain (3)  ·  Portugal (2)  ·  South Korea (2)  ·  Armenia (1)  ·  Austria (1)  ·  Brazil (1)  ·  Egypt (1)  ·  France (1)  ·  Japan (1)  ·  Malaysia (1)

Top investigators

William C. Stewart, MD (4)  ·  Abayomi Ogundele, PharmD (2)  ·  Anastasios G Konstas, MD, PhD (2)  ·  Elizabeth D. Sharpe, MD (2)  ·  Severine Durier, Pharm.D (2)  ·  Amandeep S Rai, MD (1)  ·  Anastasios GP Konstas, MD, PhD (1)  ·  Anastasios Konstas, MD, phD (1)  ·  Andrea L. Kossler, M.D. (1)  ·  Anna Grau (1)  ·  Barbara Cvenkel, MD (1)  ·  Carolina Gracitelli, Affiliate Professsor (1)  ·  Cindy M. Hutnik, BSc, PhD, MD (1)

Results publications

PMID 19476406, PMID 12614754, PMID 14509472, PMID 16303952, PMID 17102003, PMID 20505839, PMID 21773673, PMID 21960068, PMID 22458918, PMID 24855336, PMID 27913991, PMID 28239491, PMID 40341017, PMID 8562550

NIH funding

2009 (1), 2016 (1), R01EY022124 (1)